Feiger A D
Feiger Health Research Center, Wheat Ridge, CO 80033, USA.
Psychopharmacol Bull. 1996;32(4):659-65.
We report the results from one site of a two-site, double-blind, placebo-controlled comparison study of gepirone extended release (ER) and imipramine in the management of major depression. In the study, 123 subjects with DSM-III-R major depression were randomized to 8 weeks of treatment with gepirone ER (10-60 mg/day), imipramine (50-300 mg/day), or placebo. According to last observation carried forward (LOCF) analyses of 120 intent-to-treat subjects, both gepirone ER and imipramine were superior to placebo at Weeks 6 and 8 on the Hamilton Rating Scale for Depression 17- and 28-item (HAM-D-17 and HAM-D-28) instruments, the Clinical Global Impressions (CGI) Severity of illness scale, and the total Bech Six-Item Core Depression Cluster score. Gepirone ER was better tolerated than imipramine when judged by dropout rates for adverse events.
我们报告了一项关于在重度抑郁症治疗中使用缓释型阿吡哌隆（ER）和丙咪嗪的双中心、双盲、安慰剂对照比较研究中一个中心的结果。在该研究中，123名符合DSM-III-R重度抑郁症标准的受试者被随机分配接受为期8周的治疗，治疗药物分别为缓释型阿吡哌隆（10 - 60毫克/天）、丙咪嗪（50 - 300毫克/天）或安慰剂。根据对120名意向性治疗受试者的末次观察结转（LOCF）分析，在第6周和第8周时，缓释型阿吡哌隆和丙咪嗪在汉密尔顿抑郁量表17项和28项（HAM-D-17和HAM-D-28）、临床总体印象（CGI）疾病严重程度量表以及贝克六项核心抑郁症状群总分方面均优于安慰剂。根据不良事件导致的脱落率判断，缓释型阿吡哌隆的耐受性优于丙咪嗪。
